ILSI/HESI maternal toxicity workshop summary: maternal toxicity and its impact on study design and data interpretation

The Importance of the Level of Maternal Anti-Ro/SSA Antibodies as a Prognostic Marker of the Development of Cardiac Neonatal Lupus Erythematosus

(2010) Edgar Jaeggi et al.   JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY

Improved methodology for identifying the teratogenic potential in early drug development of hERG channel blocking drugs

(2010) M.F. Nilsson et al.   REPRODUCTIVE TOXICOLOGY

Are selective serotonin reuptake inhibitors cardiac teratogens? Echocardiographic screening of newborns with persistent heart murmur

(2009) Paul Merlob et al.   BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY

Considerations in assessing the developmental and reproductive toxicity potential of biopharmaceuticals

(2009) Pauline L. Martin et al.   BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY

Embryo/fetal development in cynomolgus monkeys exposed to natalizumab, an α4 integrin inhibitor

(2009) Nancy G. Wehner et al.   BIRTH DEFECTS RESEARCH PART B-DEVELOPMENTAL AND REPRODUCTIVE TOXICOLOGY

Collation, assessment and analysis of literaturein vitrodata on hERG receptor blocking potency for subsequent modeling of drugs' cardiotoxic properties

(2008) Sebastian Polak et al.   JOURNAL OF APPLIED TOXICOLOGY

The relationship of maternal and fetal toxicity in developmental toxicology bioassays with notes on the biological significance of the “no observed adverse effect level”

(2008) N. Chernoff et al.   REPRODUCTIVE TOXICOLOGY